MX2023013890A - Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. - Google Patents
Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.Info
- Publication number
- MX2023013890A MX2023013890A MX2023013890A MX2023013890A MX2023013890A MX 2023013890 A MX2023013890 A MX 2023013890A MX 2023013890 A MX2023013890 A MX 2023013890A MX 2023013890 A MX2023013890 A MX 2023013890A MX 2023013890 A MX2023013890 A MX 2023013890A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- nitrogen
- containing heterocyclic
- method therefor
- heterocyclic compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 4
- -1 Nitrogen-containing heterocyclic compound Chemical class 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410 | 2021-05-24 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202210198679 | 2022-03-02 | ||
| PCT/CN2022/094612 WO2022247816A1 (zh) | 2021-05-24 | 2022-05-24 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013890A true MX2023013890A (es) | 2023-12-11 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013890A MX2023013890A (es) | 2021-05-24 | 2022-05-24 | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (https=) |
| EP (1) | EP4349836A4 (https=) |
| JP (1) | JP2024519188A (https=) |
| KR (1) | KR20240012437A (https=) |
| CN (1) | CN117177971A (https=) |
| AU (1) | AU2022280845A1 (https=) |
| BR (1) | BR112023022496A2 (https=) |
| CA (1) | CA3219858A1 (https=) |
| MX (1) | MX2023013890A (https=) |
| TW (1) | TW202313630A (https=) |
| WO (1) | WO2022247816A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| CN120035596A (zh) * | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| AU2024286996A1 (en) | 2023-06-08 | 2026-01-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for formamide compounds |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| JP7469304B2 (ja) * | 2018-11-16 | 2024-04-16 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐａｒｐインヒビタを含む医薬組成物 |
| MX2022000711A (es) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| CN116018132A (zh) | 2020-06-24 | 2023-04-25 | Itf研究制药有限公司 | 软明胶胶囊 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
-
2022
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 TW TW111119308A patent/TW202313630A/zh unknown
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3219858A1 (en) | 2022-12-01 |
| BR112023022496A2 (pt) | 2024-01-16 |
| EP4349836A1 (en) | 2024-04-10 |
| US20240287094A1 (en) | 2024-08-29 |
| EP4349836A4 (en) | 2024-10-30 |
| JP2024519188A (ja) | 2024-05-08 |
| AU2022280845A1 (en) | 2023-12-14 |
| CN117177971A (zh) | 2023-12-05 |
| TW202313630A (zh) | 2023-04-01 |
| WO2022247816A1 (zh) | 2022-12-01 |
| KR20240012437A (ko) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2023001980A (es) | Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo. | |
| ZA202308118B (en) | Cdk inhibitor | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2022008881A (es) | Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico. | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX391655B (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo | |
| MY202371A (en) | Hexone glucokinase inhibitor and use thereof | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| WO2023078333A8 (zh) | 一种取代的苯丙酸衍生物及其用途 | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. |